Background: The Cognitive Behavioral Analysis System of Psychotherapy (CBASP), initially developed as an outpatient treatment for chronic depression (CD), has been adapted as a multidisciplinary 12-week inpatient program for CD. Methods: Seventy inpatients with CD and treatment resistance were included in a noncontrolled trial. The Hamilton Depression Rating Scale served as the primary outcome measure. Prospective naturalistic follow-up assessments were conducted 6 and 12 months after discharge. Results: Dropout rate was 7.1%; 90.4% perceived the program as helpful. Pre-post comparisons yielded strong effect sizes; 75.7% of the intention-to-treat sample responded, and 40.0% remitted. Nonremission was associated with experiencing temporary deterioration of symptoms during treatment. After 6 months 75.0% and after 12 months 48.0% of patients sustained response. Conclusions: The CBASP program appears as a feasible acute treatment for treatment-resistant CD inpatients with promising outcome. However, the continuation of treatment after discharge should be optimized especially for patients with subjective deterioration during treatment.

1.
Murphy JA, Byrne GJ: Prevalence and correlates of the proposed DSM-5 diagnosis of chronic depressive disorder. J Affect Disord 2012;139:172-180.
2.
McCullough JP: Treatment of Chronic Depression. Cognitive Behavioral Analysis System of Psychotherapy. New York, Guilford Press, 2000.
3.
Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J: A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-1470.
4.
Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP, Weiss PM, Dunner DL, Rothbaum BO, Kornstein S, Keitner G, Keller MB: Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA 2003;100:14293-14296.
5.
Schramm E, Zobel I, Dykierek P, Kech S, Brakemeier EL, Külz A, Berger M: Cognitive behavioral analysis system of psychotherapy versus interpersonal psychotherapy for early-onset chronic depression: a randomized pilot study. J Affect Disord 2011;129:109-116.
6.
Wiersma J, van Schaik DJF, Hoogendorn AW, Dekker JJ, Van HL, Schoevers RA, Blom MBJ, Maas K, Smit JH, McCullough JP, Beekman ATF, van Oppen P: The effectiveness of Cognitive Behavioral Analysis System of Psychotherapy: a randomized controlled trial. Psychother Psychosom 2014;83:263-260.
7.
Kocsis JH, Gelenberg AJ, Rothbaum BO, Klein DN, Trivedi MH, Manber R, Keller MB, Leon AC, Wisniewski SR, Arnow BA, Markowitz JC, Thase ME; REVAMP Investigators: Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. Arch Gen Psychiatry 2009;66:1178-1188.
8.
Gilmer WS, Trivedi MH, Rush AJ, Wisniewski SR, Luther J, Howland RH, Yohanna D, Khan A, Alpert J: Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. Acta Psychiatr Scand 2005;112:425-433.
9.
Hollon SD, DeRubeis RJ, Fawcett J, Amsterdam JD, Shelton RC, Zajecka J, Young PR, Gallop R: Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry 2014;71:1157-1164.
10.
Härter M, Sitta P, Keller F, Metzger R, Wiegand W, Schell G, Stieglitz RD, Wolfersdorf M, Felsenstein M, Berger M: Psychiatric-psychotherapeutic inpatient treatment for depression. Process and outcome quality based on a model project in Baden-Württemberg. Nervenarzt 2004;75:1083-1091.
11.
Brakemeier EL, Normann C: Praxisbuch CBASP. Behandlung chronischer Depression. Weinheim, Beltz, 2012.
12.
Brakemeier EL, Engel V, Schramm E, Schmidt T, Zobel I, Hautzinger M, Berger M, Normann C: Feasibility and outcome of cognitive behavioral analysis system of psychotherapy (CBASP) for chronically depressed inpatients: a pilot study. Psychother Psychosom 2011;80:191-194.
13.
American Psychiatric Association (APA): Diagnostic and Statistical Manual of Mental Disorders, ed 4, revised. Washington, APA, 2001.
14.
Thase ME, Rush AJ: Treatment resistant depression; in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995, pp 1081-1097.
15.
Middleton H, Shaw I, Feder G: NICE guidelines for the management of depression. BMJ 2005;330:26-78.
16.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:5662.
17.
Hautzinger M, Keller F, Kühner C: Beck-Depressions-Inventar (BDI-II). Revision. Frankfurt/Main, Harcourt Test Services, 2006. Deutsche Bearbeitung von Beck AT, Steer RA, Brown GK: Beck Depression Inventory-II (BDI-II). San Antonio, Harcourt Assessment Inc, 1996.
18.
Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
19.
Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH: The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996;26:477-486.
20.
Caspar F: Das Impact Message Inventory von Kiesler; in Brähler E, Schumacher J, Strauss B (eds): Diagnostische Verfahren in der Psychotherapie. Weinheim, Beltz, 2002, pp 214-216.
21.
First MB, Spitzer RL, Gibbon M, Williams JBW: Structured clinical interview for DSM-IV Axis 1 Disorders - Clinician Version (SCID-CV). Washington, American Psychiatric Press, 1997.
22.
Fydrich T, Renneberg B, Schmitz B, Wittchen HU: SKID-II Strukturiertes Klinisches Interview für DSM-IV, Achse II: Persönlichkeitsstörungen. Interviewheft. Göttingen, Hogrefe, 1997.
23.
Bernstein DP, Fink L: CTQ Childhood Trauma Questionnaire. A Retrospective Self-Report. Manual. San Antonio, The Psychological Corporation, 1998.
24.
Schafer JL, Graham JW: Missing data: our view of the state of the art. Psychol Methods 2002;7:147-177.
25.
Cohen J: Statistical Power for the Behavioral Sciences. New York, Academic Press, 1977.
26.
Feingold A: Effect sizes for growth-modeling analysis for controlled clinical trials in the same metric as for classical analysis. Psychol Methods 2009;14:43-53.
27.
R Core Team: R: a language and environment for statistical computing. Vienna, R Foundation for Statistical Computing, 2013. http://www.R-project.org.
28.
Cuijpers P, van Straten A, Schuurmans J, van Oppen P, Hollon SD, Andersson G: Psychotherapy for chronic major depression and dysthymia: a meta-analysis. Clin Psychol Rev 2010;30:51-62.
29.
Kocsis JH, Rush AJ, Markowitz JC, Borian FE, Dunner DL, Koran LM, Klein DN, Trivedi MH, Arnow B, Keitner G, Kornstein SG, Keller MB: Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Psychopharmacol Bull 2003;37:73-87.
30.
Brakemeier EL, Merkl A, Wilbertz G, Quante A, Regen F, Bührsch N, van Hall F, Kischkel E, Danker-Hopfe H, Heuser I, Kathmann N, Bajbouj M: Continuation treatment after electroconvulsive therapy in patients with unipolar depression. Biol Psychol 2014;76:194-202.
31.
Vittengl JR, Clark LA, Dunn TW, Jarrett RB: Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects. J Consult Clin Psychol 2007;75:475-488.
32.
Ebert DD, Tarnowski T, Gollwitzer M, Sieland B, Berking M: A transdiagnostic internet-based maintenance treatment enhances the stability of outcome after inpatient cognitive behavioral therapy: a randomized controlled trial. Psychother Psychosom 2013;82:246-256.
33.
Brakemeier EL, Marchner J, Gutgsell S, Engel V, Radtke M, Tuschen-Caffier B, Normann C, Berking M: CBASP@home: an internet-based situational-analysis-training as a maintenance treatment after inpatient therapy for chronically depressed patients. Themenheft: Internetbasierte Psychotherapie. Verhaltenstherapie 2013;23:190-203.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.